H H Lundbeck A-S
H
Closed
55.9 1.08
Overview
Share price change
24h
Min
54.7
Max
56.1
Income | -510M 1.1B |
|---|---|
Sales | -506M 6.5B |
P/E Sector Avg | 13.941 51.78 |
EPS | 1.54 |
Dividend yield | 2.12 |
Profit margin | 17.61 |
Employees | 5,000 |
EBITDA | -808M 2B |
Dividend yield Sector Avg | 2.12% 1.96% |
|---|
Market Cap | 11B 54B |
|---|---|
Previous open | 54.82 |
Previous close | 55.9 |
H Lundbeck A-S Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
H Lundbeck A-S Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About H Lundbeck A-S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
